Brief: Acurx Announces Additional Ibezapolstat Ph2b Results In Cdi As Well As Anthrax Susceptibility To Acx-375 Analogues
26/09/2024 12:06
Sept 26 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES ADDITIONAL IBEZAPOLSTAT PH2B RESULTS IN
CDI AS
WELL AS ANTHRAX (B. ANTHRACIS) SUSCEPTIBILITY TO ACX-375
ANALOGUES
* ACURX PHARMACEUTICALS INC: NEW ANALYSES EXTEND DATA ON
BENEFICIAL EFFECTS OF IBEZAPOLSTAT ON GUT MICROBIOME
* ACURX PHARMACEUTICALS : CONFIRMED IBEZAPOLSTAT'S FAVORABLE
PHARMACOKINETICS SHOWING LOW SYSTEMIC EXPOSURE AND HIGH COLONIC
CONCENTRATIONS
Source text for Eikon: ID:nPn7Gkfksa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln